Supertron Technologies, a developer preclinical and clinical MRI coils, probes and accessories, has raised $3.5 million in a Series C financing. Supertron is one of Amphion Innovations’s partner companies. As a result of this financing the value of Amphion’s investment in Supertron will increase from $1.1 million (from the year ended 2005) to $3.6 million.
The round was originally intended to close at $3 million, but the financing increased due to investor demand, the company said.
Amphion’s strategy is to invest in and support the growth process of companies, like Supertron, that answer broad-based, unmet market needs with proven solutions and predictable results. Supertron’s products improve the imaging capabilities of conventional MRI scanners, reduce scan time in existing scanners and greatly lower the cost. These factors ultimately result in earlier disease detection, faster drug development, and integrated and/or guided therapeutics, according to a release.
Supertron is also designing cryogenic coils that increase speed and allow for imaging of body parts in motion. The cryogenic coils also improve resolution, which enables doctors to see smaller structures. Additionally, Supertron is also targeting emerging MRI research applications in the fields of molecular imaging, image-guided therapeutics, image-guided surgery, and orthopedics imaging. The company is currently developing a number of next-generation MRI products in neuro imaging and pre-clinical imaging.